To determine the incidence and risk factors for nevirapine (NVP)-associated toxicity in a cohort of HIV-infected people in Buenos Aires, Argentina. Design: Retrospective study. Methods: HIV-infected adults who received NVP-based highly active antiretroviral therapy (HAART) at least for 2 weeks between May 1997 and March 2008 were included in this study. We analyzed patients' age, gender, HIV transmission route, HIV disease stage, pregnancy, alcohol intake, adverse events, coinfection with hepatitis B or C virus, time until toxicity, and withdrawal rates. Results: A total of 1110 patients (631 men) were included. Rash was the most frequently observed adverse event; it was more frequent in women. The incidence of severe rash and hepatotoxicity was similar in women and men. Female sex was the only variable significantly associated with mild-to-moderate rash. High CD4 count, pregnancy, and chronic hepatitis were not associated with NVP-related toxicity. An undetectable viral load at the time of starting NVPtreatment resulted in a lower risk of NVP-related rash.
Introduction
Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor drug (NNRTI), approved by US Food and Drug Administration (FDA) for the treatment of HIV-1-infected individuals on June 21, 1996 . Since then, it has been used in the treatment of HIV-1-infected adults and children and is now considered an alternative option for the treatment of HIV antiretroviral-naive patients. 1 Nevirapine is also used for the prevention of vertical transmission of HIV. Many physicians use NVP owing to its low pill burden and to avoid toxicities associated with the use of protease inhibitors (Pls).
Nevirapine is well tolerated. Its low cost, compared with other drugs, and its availability in generic co-formulation with nucleoside reverse transcriptase inhibitors (NRTIs), make it an interesting option in limited-resource countries.
The most common reported NVP-related side effects are rash and hepatotoxicity and may range from mild to life-threatening and even fatal events. 2 Rash occurs approximately in 9% to 22% of patients receiving NVP, 3 prompting its discontinuation in about 7% of patients included in pivotal clinical trials. 1 Hepatotoxicity with elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN) occurs in 5% to 10% of patients receiving NVP, 2 though the majority are asymptomatic.
Chronic viral hepatitis, excessive alcohol intake, and coadministration of other potential hepatotoxic drugs are all risk factors for the development of hepatic damage. 4, 5 Female gender, pregnancy, and CD4 count are additional risk factors for NVP toxicity. 4, 6 In 2005, the FDA recommended not to use NVP in women with CD4 count >250 cells/mm 3 and in men with >400 cells/ mm 3 due to increased risk of liver toxicity in patients with such characteristics. 7 In Argentina, we lack accurate data about the true incidence of NVP-associated toxicity. The aim of this study was to determine the incidence of NVP-associated toxicity in a cohort of HIV-infected people living in Buenos Aires, Argentina. We also tried to identify the possible risk factors associated with toxicity and to evaluate whether the FDA warning is warranted in our population.
Material and Methods
We conducted a retrospective study of HIV-infected patients assisted in 3 medical centers in Buenos Aires, Argentina.
All HIV-infected patients who were >16 years of age, and received NVP as part of their highly active antiretroviral therapy ([HAART]; 200 mg/d for the first 2 weeks and then 400 mg/d thereafter, divided in 2 doses) at least for 2 weeks between May 1997 and March 2008 were included in this study. Those patients who received drugs with NVP overlapping toxicities, such as sulfonamides and abacavir, were included in this analysis only when the timing of toxicity made the non-NVP drug clearly unrelated to the adverse event.
Medical records were reviewed and the following demographic and clinical data were collected: patient's age at the time of starting NVP, gender, HIV transmission route, HIV disease stage according to the 1993 US Centers for Disease Control and Prevention guidelines, 8 other drugs included in their HAART regimen, pregnancy, alcohol intake, adverse events, time until toxicity, and withdrawal rates.
We collected information on hepatitis B ([HBV]; HBV surface antigen [HBsAg] and hepatitis C ([HCV]; enzyme-linked immunosorbent assay immunoglobulin G [ELISA IgG]) markers, ALT and AST levels before and after starting NVP, and CD4 count, and HIV viral load before NVP treatment.
Variables Studied and Definitions
Chronic hepatitis. Patients were considered to have chronic hepatitis when HBsAg or anti-HCV antibodies were detected in the plasma.
Excessive alcohol intake. Men and women were considered heavy alcohol consumers if they drank more than 252 and 168 g of alcohol per week, respectively. 9, 10 Intravenous drug users (IVDU). People who reported previous or actual use of intravenous illicit drugs.
NVP-PI HAART. A combination of antiretroviral (ARV) drugs including NVP plus a Pl.
Pregnant women. Pregnant women included in our study were divided in 2 groups according to the initiation of NVP that is before or after conception.
High CD4 count. CD4 count >250 cells/mm 3 for women and >400 cells/mm 3 for men.
Mild-to-moderate rash. Any isolated skin eruption occurring at any time after the patient started NVP, without fever or constitutional symptoms.
Severe rash. A cutaneous eruption associated with fever or constitutional symptoms, or any cutaneous toxicity prompting the physician to withdraw the drug, independently of clinicalassociated characteristics.
NVP-associated hepatotoxicity. Elevation of AST or ALT >5Â ULN for patients with previous normal levels, or >3.5Â baseline for those who had abnormal basal levels.
Time on NVP until toxicity. Elapsed time between the start of NVP and the first manifestation of NVP-related toxicity.
Statistical Methodology
Quantitative variables (age, CD4 count, and time on NVP until toxicity) were described with median and interquartile range due to their abnormal distribution. Differences between men and women were analyzed with nonparametric Wilcoxon rank sum test (Tables 1 and 2 ). Any other variable was described by means of proportions and percentages, and the differences between proportions and percentages were analyzed with chisquare or Fisher exact test (Tables 1 to 4) .
Differences were considered statistically significant for P < .05, 2-tailed tests. An univariate analysis was performed with the variables hypothesized as risk factors for NVP-associated toxicity (dependent variable). All the variables were included in the multivariate analysis because they were of interest for the incidence of toxicity.
Cox regression analysis was performed for each category of toxicity and hazard ratio (HR), 95% confidence interval (CI) and the value of P are shown in Table 5 .
Time on NVP until toxicity was studied with Kaplan-Meier survival analysis and log rank test was applied for significance between women and men. Overall median time estimate without toxicity as well as median time by gender and corresponding 95% CI are given. Kaplan-Meier plots are shown. Data analysis was performed with SPSS 15.0, 2007 (Chicago, IL).
Results
During the study period, 1110 patients were included, 631 men and 479 women. Median follow-up was 19 months (IQR 5-53) and 27 months (IQR 9-57) for women and men, respectively. Men were significantly older, had more advanced HIVdisease, had more frequently chronic viral hepatitis, were more frequently IVDU, and heavier alcohol consumers than women. CD4 count at the time of NVP initiation was similar in both groups, but the proportion of patients with high CD4 count was significantly higher among men. The proportion of patients with undetectable HIV viral load at the time NVP was started was similar in men and women. Table 1 presents the characteristics of the study population.
Rash was the most frequently observed adverse event, and it was more frequent in women than men (14% vs 8.7%; P ¼ .007). The incidence of severe rash and hepatotoxicity was similar in women and men. Women developed toxicities earlier.
Severe side effects prompted NVP discontinuation in 54 women and 53 men. The rates of discontinuation of NVP were similar in women and men (11.3% vs 8.4%; P ¼ NS). Table 2 shows the incidence of toxicities according to sex. Figure 1 shows differences in time until the first manifestation of toxicity in men and women.
A total of 163 women were pregnant. Data about the time they started NVP was available for 154 of them. Thirty-six started NVP before becoming pregnant. No adverse event was observed among them. The incidence of toxicity among the remaining 118 pregnant women was similar to that observed in nonpregnant women (Table 3) .
We studied the relationship between a high CD4 count before starting NVP and toxicity. We found no significant difference in the incidence of NVP-toxicity or drug-withdrawal between patients of the same gender, regardless of their CD4 count (Table 4 ). We then analyzed the association of the selected variables with NVP-related toxicity and drug withdrawal.
In univariate analysis, female gender reached a significant association with NVP-related mild-to-moderate rash (HR 1.61, 95% CI 1.15-2.25; P ¼ .007; data not shown).
In multivariate analysis, female gender remained significantly associated with mild-to-moderate rash (HR 1.95, 95% CI 1.19-3.20; P ¼ .008). An undetectable viral load at the time of starting NVP treatment was associated with a lower risk of NVP-related rash (HR 0.46, 95% CI 0.24-0.87; P ¼ .016).
No variable was associated with severe rash, NVPwithdrawal, or hepatotoxicity ( Table 5 ).
Discussion
This study is, to our knowledge, the first one conducted to evaluate NVP-associated toxicity in routine clinical practice in HIV-infected patients in Latin America, including pregnant women.
We found the incidence of cutaneous and liver toxicity similar to previously reported studies. 11, 12 Nevirapin-induced-rash was related to female gender and more frequent in patients who had a detectable HIV viral load than in those whose HIV viral load was undetectable. Our findings of higher incidence of rash in women than men, and a protective effect of undetectable viral load on the risk of rash, 13 have been reported by other studies. 14, 15 Unlike previous reports, 5, 16 we found no increase in NVPinduced hepatotoxicty in patients with chronic viral hepatitis, alcohol use, or a high CD4 count.
Pregnant women who started NVP after conception showed a higher incidence of adverse events than those who started the drug before pregnancy. We found no adverse reaction in the latter group. The different incidence of adverse events between both groups of pregnant women reached statistical significance only for mild-to-moderate rash (0 of 36 vs 16 of 118, P ¼ .024) but not for severe rash (0 of 36 vs 6 of 118, P ¼ NS) or hepatotoxicity (0 of 36 vs 3 of 118, P ¼ NS). The different incidence of rash is easily explained because it usually occurs within the first weeks of treatment. 2 Regarding similar incidence of other adverse events, we could not draw any firm conclusion because the low number of patients included.
Several studies of different design, with diverse number of patients, and carried out on different ethnic populations, were published to find a factor to predict the chance of NVP toxicity. The results were heterogeneous.
Some authors described a relationship between NVPinduced toxicity and ethnicity, 17 a history of drug allergy, 18 body mass index, 19 older age, 20 high ALT or AST level in plasma, 20 or a high CD4 count 21 before starting NVP, HCV, or HBV coinfection, 16 the carriage of the HLA-Cw8 antigen 22 or the HLA-DRB1*01 allele, 23 or mutations in MDR1 gen, 24 excessive alcohol consumption, 5 the concomitant use of PI 25 and pregnancy. 26 Other studies, evaluating the same variables, found antagonistic results. 17, [27] [28] [29] [30] There are 2 previous experiences from South America evaluating NVP-associated toxicity, both in pregnant women.
João et al found a low toxicity rate (5.6%) and a link between NVP-related adverse events and HCV coinfection. 31 In the other study, Kondo et al 32 described a higher toxicity rate (22.6%), and a relationship between liver toxicity and a CD4 count >250 cells/mm 3 .
The underlying reasons for discrepant results between the studies are unknown. However, some investigators speculate that ethnicity or genetic characteristics, may contribute significantly to the risk of NVP-associated toxicity. Several publications support that hypothesis.
Mazhude et al did not find higher rates of rash among black than white patients 14 ; but Kesselring et al, in a multicenter study, found a higher risk of hypersensitivity reactions among Asian patients. 13 Among them, Zhou et al found a higher rate of rash among Filipino and Thai than among Chinese and Indian patients. 17 Phillips et al found no difference in the rate of rash according to caucasian or aboriginal origin of patients. 29 Snijdewind et al reported that women originating from sub-Saharian Africa have a lower risk of rash than women from West Europe. 26 The role of CD4 count seems to differ in individuals of different ethnic background. In United States, Aaron et al 30 found a link between a high CD4 count and risk of hepatotoxicity and rash; and Bersoff-Matcha et al 15 reported a higher risk for severe rash and discontinuation in women with baseline CD4 count >200 cells/mm 3 . Several European researchers reported no relationship between a high CD4 count and side effects. 27, 33, 34 Among pregnant women, reports from Mozambique, 21 Brazil, 32 Ireland, 34 Thailand, 35 and United States 36 describe a high risk to develop side effects if NVP is started at a high CD4 count, but other reports found not such relationship. [37] [38] [39] Based on our findings, we have found no evidence that the FDA warning is warranted to the population studied here.
This study has many limitations. It is retrospective, the patients were evaluated by different physicians without a standardized approach, and the number of pregnant women and HCV-/HBV-coinfected patients included is small.
Finally, we cannot extrapolate our findings to the rest of Argentina or Latin America due to the European background of the majority of people living in Buenos Aires. 40 At this time, we face the following dilemma: Should we consider the FDA warning as inappropriate for our patients, or should we observe it and restrict NVP for HIV-infected patients with low CD4 counts?
We think it seems premature to discourage the use of NVP (an easily administered, affordable, and well-tolerated ARV drug) in HIV-infected patients with high CD4 count in Buenos Aires. The potential serious consequences of hepatotoxicity in pregnant women and HCV-/HBV-coinfected patients demand caution when using NVP in these group of HIV-infected individuals.
Further research is needed in people from our region, including a larger number of patients, especially those coinfected with HBV and HCV viruses as well as pregnant women to answer our questions.
